BioAtla Inc Ordinary Shares BCAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BCAB is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $2.63
- Day Range
- $2.52–2.75
- 52-Week Range
- $1.24–4.07
- Bid/Ask
- $2.50 / $2.53
- Market Cap
- $121.68 Mil
- Volume/Avg
- 564,399 / 535,933
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 65
- Website
- https://www.bioatla.com
Comparables
Valuation
|
Metric
|
BCAB
|
CGEM
|
ACLX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.79 | 1.64 | 5.95 |
Price/Sales | — | — | 24.06 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BCAB
|
CGEM
|
ACLX
|
|---|---|---|---|
Quick Ratio | 3.93 | 16.60 | 5.94 |
Current Ratio | 4.11 | 17.07 | 6.06 |
Interest Coverage | — | — | −23.39 |
Quick Ratio
BCAB
CGEM
ACLX
Profitability
|
Metric
|
BCAB
|
CGEM
|
ACLX
|
|---|---|---|---|
Return on Assets (Normalized) | −62.39% | −24.60% | −6.26% |
Return on Equity (Normalized) | −87.70% | −25.95% | −12.08% |
Return on Invested Capital (Normalized) | −90.41% | −29.67% | −13.11% |
Return on Assets
BCAB
CGEM
ACLX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bfpkgbyr | Dwvv | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ctptsxr | Nqfvyyh | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dxlgfrq | Btpbcp | $98.9 Bil | |
MRNA
| Moderna Inc | Fljpsnddy | Jjn | $39.7 Bil | |
ARGX
| argenx SE ADR | Ffczcthxb | Tdsjz | $22.1 Bil | |
BNTX
| BioNTech SE ADR | Ncdrwwcpm | Nwxh | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fyklljpf | Wycnqhn | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pprvgyt | Qnzmmp | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ylbxxgsy | Hhktg | $12.3 Bil | |
INCY
| Incyte Corp | Dslkctxc | Hhtdff | $11.8 Bil |